Enzymes

Please note this product may be subject to fees, we invite you to contact your local office. The TRα-GAL4 Luciferase Reporter HEK293 Cell Line is a HEK293 cell line expressing firefly luciferase under the control of the GAL4 upstream activation sequence (UAS) with constitutive expression of human thyroid receptor α ligand binding domain fused to the DNA binding domain (DBD) of GAL4 (GAL4 DBD). This system allows specific detection of thyroid hormone-induced activation of the thyroid receptor α with low cross-reactivity from other nuclear receptors. This cell line has been validated by stimulation with triiodothyronine (T-3).

Retatrutide (LY3437943) is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R) of interest in the treatment of obesity.

Retatrutide (LY3437943) is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R) of interest in the treatment of obesity.

Retatrutide (LY3437943) is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R) of interest in the treatment of obesity.

Exendin-4 (Exenatide), a 39 amino acid peptide, is a long-acting GLP-1 ( glucagon-like peptide-1) receptor agonist that promotes insluin secretion, and of potential use in the treatment of MASH.

Exendin-4 (Exenatide), a 39 amino acid peptide, is a long-acting GLP-1 ( glucagon-like peptide-1) receptor agonist that promotes insluin secretion, and of potential use in the treatment of MASH.

Lixisenatide is a GLP-1 (glucagon-like peptide-1) receptor agonist used in the treatment of type 2 diabetes (T2D). Lixisenatide inhibits the inflammatory response through down regulation of proinflammatory cytokines, and blocks of cellular signaling pathways.

Lixisenatide is a GLP-1 (glucagon-like peptide-1) receptor agonist used in the treatment of type 2 diabetes (T2D). Lixisenatide inhibits the inflammatory response through down regulation of proinflammatory cytokines, and blocks of cellular signaling pathways.

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. Semaglutide is used in the treatment of type 2 diabetes (T2D) and obesity.